INDIAN-IMMIGRATION
8.6.2022 10:02:10 CEST | Business Wire | Press release
India has recently become a popular tourist destination for travelers thanks to the breathtaking sceneries it has to offer. Besides adventure travel and cultural tours, wellness tourism in India has emerged as a significant and rapidly expanding tourism segment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005070/en/
The growth of wellness tourism in India
In 2020, India ranked 12th in the top 20 largest wellness tourism markets in the world, with more than 48.2 million wellness trips. Making use of this travelers' interest, India offers plenty of wellness retreats and resorts for tourists as well as advantageous conditions to get Indian visas.
Many travelers may be confused about the difference between wellness tourism and medical tourism . Medical tourism is about traveling to a different place for specific medical treatments while wellness tourism is associated with the pursuit of maintaining or enhancing travelers’ wellbeing.
Especially, more people are choosing health and wellness tourism in India to recharge their batteries and refresh themselves post pandemic.
Lauren Jane, an American traveler who had a wellness vacation in Ananda in the Himalayas Resort, India, says: “The activities here help me re-balance and relieve stress after the pandemic, while the healthy organic cuisine maintains my health during the trip. I will come back to experience more wellness tourism destinations in India.”
Typical types of wellness tourism in India and corresponding entry documents
India focuses on promoting wellness tourism in 03 key sectors: Meditation, yoga, and massage therapies.
One of the most popular activities on a wellness trip in India is meditation. Travelers will participate in meditation activities in a natural space of plants, water, and clouds. Meditation is a good way for tourists to reset their bodies, and enjoy the moments of relaxation in their souls.
Known as the birthplace of yoga, India promotes the construction of wellness retreats suitable for yoga practices. Most of the retreats are settled close to nature, surrounded by the lush green forests, providing tourists with quiet spaces for doing yoga.
Ayurvedic massage is unique in many wellness retreats in India, bringing relaxing and soothing experiences for tourists. This massage therapy uses oils, herbs, and natural products to help tourists relieve emotional stress, rejuvenate their mind and soul.
“To experience wellness tours in India, travelers just need to prepare a valid passport to apply for an Indian visa, ” said Mrs. Kim, Relationship Manager in Indian Immigration Services.
Useful tips for tourists from Indian Immigration Service Experts
For a pleasant trip to India, travelers should get a visa beforehand. “To choose a reliable partner for making an eVisa, travelers need to consider factors including the fees, processing time, and professionalism of the staff,” Mrs. Kim also said.
Instead of visiting the embassy to apply for a India visa, foreign travelers can obtain an eVisa on the Indian Immigration Services website. As an applicant, travelers need to meet the visa requirements to be granted an Indian eVisa for tourists.
India Immigration Services makes it easier for travelers to apply for an Indian visa online with reasonable Indian eVisa fees. We assisted more than 25,000 customers globally in making eVisas to India. In addition, we also offer Travel Insurance in order to help our customers cover the cost of medical treatments during the trip.
No more complicated process to get a Visa to enter India, travelers now can expect to have a memorable wellness trip in this fascinating country with India Immigration Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005070/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom